Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14121560 | 0.92 | OPRM1 (0.46) | OPRM1KMT2AOPRL1MEN1 | |
| SCHEMBL6202800 | 0.85 | OPRM1 (0.41) | OPRM1KMT2AOPRL1ALDH1A1 | |
| SCHEMBL6180992 | 0.80 | ALDH1A1 (0.42) | OPRM1KMT2AOPRL1WDR5MEN1 | |
| SCHEMBL3171333 | 0.79 | WDR5 (0.47) | OPRM1KMT2AWDR5MEN1NPC1 | |
| SCHEMBL17632371 | 0.77 | WDR5 (0.46) | OPRM1KMT2AWDR5MEN1NPC1 | |
| SCHEMBL24044974 | 0.76 | OPRM1 (0.46) | OPRM1KMT2AOPRL1MEN1 | |
| SCHEMBL16691395 | 0.76 | KMT2A (0.46) | OPRM1KMT2AMEN1NPC1ALDH1A1 | |
| SCHEMBL1020648 | 0.76 | SLC6A4 (0.49) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL1019371 | 0.76 | SLC6A4 (0.53) | OPRM1KMT2AOPRL1MEN1NPC1 | |
| SCHEMBL6203572 | 0.76 | KMT2A (0.42) | OPRM1KMT2AWDR5MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | OPRM1 124/4885KMT2A 3959/4885OPRL1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.